Addressing the Challenge of Dispersed Data
For years, adipose tissue research has generated vast amounts of omics data, but these datasets remained scattered across different repositories, making comprehensive analysis challenging. Adiposetissue.org now brings insights together, integrating transcriptomic and proteomic with clinical data from more than 6,000 individuals, enabling researchers to explore obesity-related changes, weight-loss effects, and cellular mechanisms with unprecedented depth.
“We developed this knowledge portal to make adipose tissue data accessible to everyone, even those without expertise in bioinformatics,” says Dr. Lucas Massier, researcher at the Helmholtz Institute for Metabolic, Obesity and Vascular Research (short: HI-MAG) – a Helmholtz Munich institute at the University of Leipzig and the University of Leipzig Medical Center.
A key part of this effort was led by early-career scientists Jiawei Zhong and Dr. Danae Zareifi from Karolinska Institutet. “We ensured that data from different sources could be compared by standardizing terminology. Since little proteomic data was available, we also generated new protein profiling datasets, improving the portal’s ability to verify gene activity findings,” Jiawei Zhong and Danae Zareifi explain.
“By breaking down barriers to data accessibility and enabling large-scale analysis, Adiposetissue.org is a powerful resource for researchers studying adipose biology and metabolic diseases,” says Prof. Mikael Rydén, head of the endocrinology unit and co-leader of the Rydén & Mejhert lab together with assoc. Prof. Niklas Mejhert at Karolinska Institutet and Steno Diabetes Center Copenhagen. “This has been a major collaborative effort, and we will continue expanding the portal with new results in future updates.”
Key Features of Adiposetissue.org
Visit https://www.adiposetissue.org/ .
About the Researchers
Dr. Lucas Massier, Junior research group leader at the Helmholtz Institute for Metabolic, Obesity and Vascular Research (short: H-MAG) – a Helmholtz Munich institute at the University of Leipzig and the University of Leipzig Medical Center, and scientist at Karolinska Institutet
Prof. Mikael Rydén, Head of the endocrinology unit at the Department of Medicine (H7) at Karolinska Institutet, senior consultant at the Karolinska University Hospital and researcher at Steno Diabetes Center Copenhagen
Assoc. Prof. Niklas Mejhert, Endocrinology unit at the Department of Medicine (H7) at Karolinska Institutet, and researcher at Steno Diabetes Center Copenhagen
Jiawei Zhong, PhD student, Department of Medicine (H7) at Karolinska Institutet
Dr. Danae Zareifi, postdoctoral fellow, Department of Medicine (H7) at Karolinska Institutet
About Helmholtz Munich
Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of diabetes, obesity, allergies, and chronic lung diseases. With the power of artificial intelligence and bioengineering, researchers accelerate the translation to patients. Helmholtz Munich has around 2,500 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 43,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): www.helmholtz-munich.de/en
Cell Metabolism